Sustainable and Healthy Return-to-Work Program - PRATICAdr 2.0 (PRATICAdr)

May 27, 2026 updated by: Marc Corbière, Université du Québec a Montréal

Sustainable and Healthy Return-to-Work Program for Employees of Large Healthcare Organizations - PRATICAdr 2.0

This study aims to assess the effectiveness of PRATICAdr 2.0, a web application facilitated by a Return-to-Work Coordinator (RTW-C), with a focus on reducing sick leave duration and preventing relapse in individuals with CMDs. PRATICAdr 2.0 designed to enhance collaboration among Return-to-Work (RTW) stakeholders and provide systematic support throughout the RTW process, is evaluated in a randomized control trial (RCT). As part of the RCT, a total of 80 sick leave employees from 4 large public health organizations (n=80, 40 from the experimental group and 40 from the control group) will be recruited. The control group receives usual services offered by a RTW-C to sick leave employees, while the experimental group receives RTW-C services plus the use of PRATICAdr 2.0.

Study Overview

Detailed Description

Common mental disorders (CMDs) are highly prevalent in workplace settings, and have become a significant public health challenge. This study aims to assess the effectiveness of PRATICAdr 2.0, a web application facilitated by a Return-to-Work Coordinator (RTW-C), with a focus on reducing sick leave duration and preventing relapse in individuals with CMDs. PRATICAdr 2.0 designed to enhance collaboration among Return-to-Work (RTW) stakeholders and provide systematic support throughout the RTW process, is evaluated in a randomized control trial (RCT). As part of the RCT, a total of 80 sick leave employees from 4 large public health organizations (n=80, 40 from the experimental group and 40 from the control group) will be recruited. The control group receives usual services offered by a RTW-C to sick leave employees, while the experimental group receives RTW-C services plus the use of PRATICAdr 2.0. Participants will be randomly assigned to either the PRATICAdr 2.0 experimental group or the control group using computerized stratified randomization based on age, site, and sex (sealed envelope method). Participants will complete a series of online questionnaires at several following time points. Survival analyses were used to compare sick leave durations and relapses between the experimental group (PRATICAdr with RTW-C), and control groups (RTW-C only). Mixed linear models were used to observe changes in clinical symptoms over time, especially for the experimental group.

Study Type

Interventional

Enrollment (Actual)

49

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montreal, Quebec, Canada, H3C 3P8
        • Université du Québec à Montréal (UQAM), Department of Education and Pedagogy, Career Counselling

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Sick leave due to Common mental disorder (i.e. depression, anxiety, adjustment disorder, burnout)
  • Sick leave duration (from 1 to 3 months)
  • Member of participating unions in the large health organization

Exclusion Criteria:

  • Inability to communicate in French
  • Have a known organic disorder
  • Have a professional dirsorder (CNESST)
  • Have experienced previous sick leaves due to Common mental disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Return to work coordinator + PRATICAdr 2.0

The primary objective of the Return to work coordinator (RTW-C) is to coordinate, plan, and promote sustainable RTW for employees on sick leave.The RTW-C is responsible for assessing employee functioning while exploring barriers to RTW and available resources to develop a RTW plan. Also, RTW-C enhance communication and collaboration among stakeholders involved in the RTW process.

In this arm, the RTW-C uses PRATICAdr 2.0, a web application including key features (e.g., Facilitation of collaboration among multiple RTW stakeholders across healthcare, enterprise, and insurance sectors; Integration of each stakeholder's action into the sick leave employee's RTW process; sequential process aligned with the three phases of the RTW, inclusion of tools).

The Return to work coordinator (RTW-C) uses PRATICAdr. 2.0 (web application).
Sham Comparator: Return to work coordinator only

The primary objective of the Return to work coordinator (RTW-C) is to coordinate, plan, and promote sustainable RTW for employees on sick leave.The RTW-C is responsible for assessing employee functioning while exploring barriers to RTW and available resources to develop a RTW plan. Also, RTW-C enhance communication and collaboration among stakeholders involved in the RTW process.

In this arm, the RTW-C does not use PRATICAdr 2.0.

The Return to work coordinator (RTW-C) intervenes on employees on sick leave as usual

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sick leave duration
Time Frame: through study completion, an average of 2 years
The number of days during the sick leave
through study completion, an average of 2 years
Relapses
Time Frame: through study completion, an average of 2 years
Number of relapses after returning to work
through study completion, an average of 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depressive symptoms
Time Frame: through study completion, an average of 2 years
Patient Health Questionnaire for depression (PHQ-9; Kroenke et al., 2001)
through study completion, an average of 2 years
Anxiety symptoms
Time Frame: through study completion, an average of 2 years
Generalized Anxiety Disorder Scale (GAD-7; Spitzer et al., 2006)
through study completion, an average of 2 years
Return to Work Obstacles and Self-Efficacy
Time Frame: through study completion, an average of 2 years
Return to Work Obstacles and Self-Efficacy Scale (ROSES ; Corbière et al., 2017 )
through study completion, an average of 2 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Social functioning
Time Frame: through study completion, an average of 2 years
WHODAS
through study completion, an average of 2 years
Working alliance
Time Frame: through study completion, an average of 2 years
Working Alliance Inventory (Horvath & Greenberg, 1989; Corbière et al., 2006)
through study completion, an average of 2 years
Work accommodations
Time Frame: through study completion, an average of 2 years
Work Accommodation and Natural Support Scale (WANSS; Corbière et al., 2014)
through study completion, an average of 2 years
Work recognition
Time Frame: through study completion, an average of 2 years
Recognition by stakeholders of returning to work following a common mental disorder (RECONNECT, Corbière, Larivière, Charette-Dussault, 2021)
through study completion, an average of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 6, 2024

Primary Completion (Actual)

April 15, 2026

Study Completion (Actual)

April 15, 2026

Study Registration Dates

First Submitted

April 5, 2024

First Submitted That Met QC Criteria

April 29, 2024

First Posted (Actual)

May 2, 2024

Study Record Updates

Last Update Posted (Actual)

May 29, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Common Mental Disorder

Clinical Trials on Return to work coordinator + PRATICAdr 2.0

Subscribe